Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R is hydrogen or C alkyl； R is hydrogen, C alkyl, C(O)OH, C(O)NH or (C alkylene)R； R and R are independently hydrogen, C alkyl or R together with R and together with the carbon atom to which they are attached form a C cycloalkyl group； R is C alkyl, C alkoxy or halogen； R and R are independently hydrogen, hydroxy, halogen, C(O)NH, C(O)OH or (C alkylene) R； R and R are independently hydrogen or halogen； R is hydrogen, (C alkylene)R, C(O)NH, C(O)OH or R together with R form a 6 membered heterocyclic ring optionally containing a further heteroatom selected from oxygen, sulphur or nitrogen； R is hydrogen, halogen, hydroxy, C(O)NH, C(O)NH(C alkyl), C(O)N(C alkyl) or C(O)OH； n is O, 1 or 2. processes for their preparation, to compositions containing them and to their use in the treatment of diseases and conditions for which antagonism of NK1 is beneficial.
